HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

Abstract
The prognostic value of serum beta 2 microglobulin (s beta 2m) measured at entry, at plateau and at 3-monthly follow-up times has been assessed for patients in the Medical Research Council's 4th and 5th Myelomatosis Trials. Analysis of 1014 patients confirmed the value of presentation s beta 2m of predicting survival in the short term but showed that predictive value was lost for subsequent survival in those patients who had survived for at least 2 years. However, measurements of s beta 2m taken during follow-up were predictive of subsequent survival. The predictive power of these follow-up measurements was very similar to that for the presenting measurement, and again they were only of value in predicting survival in the next 2 years.
AuthorsJ Cuzick, B L De Stavola, E H Cooper, C Chapman, I C MacLennan
JournalBritish journal of haematology (Br J Haematol) Vol. 75 Issue 4 Pg. 506-10 (Aug 1990) ISSN: 0007-1048 [Print] England
PMID2119793 (Publication Type: Journal Article)
Chemical References
  • Hemoglobins
  • Immunoglobulin Heavy Chains
  • Immunoglobulin Light Chains
  • beta 2-Microglobulin
  • Creatinine
  • Calcium
Topics
  • Calcium (blood)
  • Creatinine (blood)
  • Hemoglobins (analysis)
  • Humans
  • Immunoglobulin Heavy Chains (analysis)
  • Immunoglobulin Light Chains (analysis)
  • Multiple Myeloma (blood, drug therapy, mortality)
  • Prognosis
  • Time Factors
  • beta 2-Microglobulin (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: